Author

Hiroshi Ueda

Kyoto UniversityORCID 0000-0002-8002-0137Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Assay:fluorescence / live-cell microscopy· 1 Research Focus:host-pathogen & immune response· 1 Approach:microscopy & imaging analysis· 1

Frequent Co-Authors

Akihiro KusumiiD· 1 shared Hiroki NakajimaiD· 1 shared Hiroyuki NeyamaiD· 1 shared Hisashi ShirakawaiD· 1 shared Jerold J. M. ChuniD· 1 shared Kazuki NagayasuiD· 1 shared Kazunao Taniyama· 1 shared Masayuki SakamotoiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiophysics

Akihiro KusumiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Single-molecule detection of transient dimerization of opioid receptors 2: Heterodimer blockage reduces morphine tolerance

Peng Zhou, Rinshi S. Kasai, Wakako Fujita, Taka A. Tsunoyama, Hiroyuki Neyama, Hiroshi Ueda, Tatsushi Yokoyama, Masayuki Sakamoto, Simone Pigolotti A, Takahiro K. Fujiwara, Akihiro Kusumi

The paper uses single-molecule imaging to study opioid receptor heterodimerization and shows that blocking MOR-DOR heterodimers reduces morphine tolerance in mice.

Nature Communications · Nov 7, 2025Peer-reviewedBiophysics

Lysophosphatidic acid receptor 1 influences disease severity in a mouse model of multiple sclerosis

Nagi Uemura, Nagisa Matsuo, Kazunao Taniyama, Hiroki Nakajima, Kazuki Nagayasu, Shuji Kaneko, Jerold J. M. Chun, Hiroshi Ueda, Hisashi Shirakawa

This study shows that LPA1 receptor activation worsens multiple sclerosis in mice by promoting microglial activation and immune cell infiltration, and that blocking LPA1 improves disease outcomes.

bioRxiv · May 28, 2024 · PreprintNeuroscience